로딩 중…
StockDiggingStockDigging

Grifols, S.A.

GRFS· NASDAQ
ESES
$8.08+0.50%
2026-10-30

Financials

Valuation Metrics

Grifols, S.A.'s Market Cap is $5.50B. At end of 2025 it was $4.95B. Ranked #1285 of 3,116 in US market (top 41%), #429 of 1,472 on NASDAQ (top 29%), #72 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.

Investment Metrics(as of 2026-10-30)

MetricValue
Size
Market Cap$5.50B
Revenue$8.39B
Net Income$511M
Total Assets$23.60B
Net Assets$6.52B
Employees25,258
Value
P/E10.76x
P/B0.84x
PEG0.21x
P/S0.66x
EV/EBITDA7.54x
FCF Yield14.77%
Profitability
ROE7.85%
ROA2.17%
Op. Margin16.66%
Revenue Growth-0.21%
Earnings Growth52.13%
Financial Health
Debt Ratio218.36%
Total Debt$10.01B
FCF$812M
Cash$603M
Current Ratio2.37x
Net Debt/EBITDA4.76x
Dividend
Div. Yield2.63%
Div. Growth12680.48%
Performance
1Y Return-11.79%
1M Return10.53%
From 52W High-18.38%
1Y MDD-27.78%
Trading
Volume767,119 shares
Trading Value$6M
Per Share
EPS$0.75
BPS$9.57

Company Info

CEO Jose Ignacio Abia Buenache
Employees 25,258
HQ Barcelona, ES

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.